西黄丸联合唑来磷酸注射液治疗乳腺癌骨转移癌的临床研究  

Treating Breast Cancer with Bone Metastasis Using Combined Xihuangwan and Zoledronic Acid Injection

作　　者：贾文娟[1] 田菲[1] 邢秀玲[1] 张莉[2] 

机构地区：[1]天津中医药大学第一附属医院肿瘤科,天津300193 [2]天津中新药业乐仁堂制药厂,天津300457

出　　处：《世界科学技术-中医药现代化》2009年第3期450-453,共4页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

摘　　要：目的:探讨西黄丸联合唑来磷酸注射液治疗乳腺癌骨转移的临床治疗作用及特点,以及西黄丸对其增效、减毒作用。方法:将120例乳腺癌骨转移癌患者随机分成3组,中药组(西黄丸)40例,综合组(西黄丸+唑来磷酸注射液)40例,对照组(唑来磷酸注射液)40例,连续2个疗程后,进行骨痛、免疫功能、K氏评分、临床受益反应(CBR)及毒副作用评价。结果:不同组别对改善疼痛等均有不同的疗效,综合组总有效率为82.5%,中药组为60.0%,对照组为67.5%;综合组在提高骨质修复能力、调节免疫功能,提高患者的生存质量,减少不良反应的发生方面也有明显优势。结论:唑来磷酸注射液与西黄丸联合应用可以显著提高乳腺癌骨转移癌的临床疗效。Here, authored discussed the clinical treatment of breast cancer with bone metastasis through a combined approach using both Xihuangwan and Zoledronic acid infection. The therapeutic and toxicity reducing effects associated with the treatment were also discussed. In the study, 120 bone metastasis patients were randomly split into 3 groups with 40 members for each. They are Chinese medicine group （Xihuangwan）, combined treatment group （Xihuangwan and Zoledronic acid injection）, and the controls （Zoledronic acid injection only）. After two rounds of continuous treatment, a range of indicators, including feel of pain, immune functions, K grades, clinical benefit response （CBR）, and toxic side effects were evaluated. Results indicate that different groups were differed in pain reducing effects. The combined treatment group registered a total effectiveness of 82.5%, with Chinese medicine group at 67.5%, and the controis at 56.1%. Apparently, the combined treatment works better in repairing ossein, enhancing immune functions, improving patient＇s life quality, and reducing the negative response to the treatment. It is believed that the combined treatment using both Zoledronic acid injection and Xihuangwan is able to enhance the therapeutic effects of breast cancer with bone metastasis.

关 键 词：骨转移癌 唑来磷酸注射液 西黄丸 临床受益反应 

分 类 号：R737.9[医药卫生—肿瘤] R917[医药卫生—临床医学]